Literature DB >> 27308560

Targeting translesion synthesis to facilitate the eradication of ovarian cancer stem cells by platinum-based therapy.

Amit Kumar Srivastava1, Qi-En Wang1.   

Abstract

Understanding the mechanisms by which cancer stem cells (CSCs) survive chemotherapy is essential for the development of new therapies. Recently, we demonstrated that ovarian CSCs survive cisplatin treatment through enhanced expression of DNA polymerase η (Pol η). Identification of micro RNA-93 (miR-93) as the regulator of Pol η provides a novel target to improve the outcome of platinum-based therapy.

Entities:  

Keywords:  Cancer stem cell; DNA repair; cisplatin resistance; translesion synthesis

Year:  2015        PMID： 27308560      PMCID： PMC4845331          DOI： 10.1080/23723556.2015.1043482

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.

Authors:  Amit Kumar Srivastava; Chunhua Han; Ran Zhao; Tiantian Cui; Yuntao Dai; Charlene Mao; Weiqiang Zhao; Xiaoli Zhang; Jianhua Yu; Qi-En Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

3.  Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development.

Authors:  K Moitra; H Lou; M Dean
Journal:  Clin Pharmacol Ther       Date:  2011-03-02       Impact factor: 6.875

Review 4.  Progress in microRNA delivery.

Authors:  Yu Zhang; Zaijie Wang; Richard A Gemeinhart
Journal:  J Control Release       Date:  2013-09-25       Impact factor: 9.776

5.  A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents.

Authors:  Yih-wen Chen; James E Cleaver; Fumio Hanaoka; Ching-fang Chang; Kai-ming Chou
Journal:  Mol Cancer Res       Date:  2006-04       Impact factor: 5.852

6.  Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.

Authors:  Ye Zhao; Christian Biertümpfel; Mark T Gregory; Yue-Jin Hua; Fumio Hanaoka; Wei Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-23       Impact factor: 11.205

Review 7.  DNA damage repair pathways in cancer stem cells.

Authors:  Marcello Maugeri-Saccà; Monica Bartucci; Ruggero De Maria
Journal:  Mol Cancer Ther       Date:  2012-07-25       Impact factor: 6.261

8.  The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts.

Authors:  Ekaterina Bassett; Nicole M King; Miriam F Bryant; Suzanne Hector; Lakshmi Pendyala; Stephen G Chaney; Marila Cordeiro-Stone
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 9.  DNA polymerases as therapeutic targets.

Authors:  Anthony J Berdis
Journal:  Biochemistry       Date:  2008-07-19       Impact factor: 3.162

Review 10.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  EMBO Mol Med       Date:  2012-02-20       Impact factor: 12.137
  10 in total
  2 in total

Review 1.  Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities.

Authors:  Maroof K Zafar; Robert L Eoff
Journal:  Chem Res Toxicol       Date:  2017-09-28       Impact factor: 3.739

2.  Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: a study of 187 cases.

Authors:  Jiang-Hui Zeng; Dan-Dan Xiong; Yu-Yan Pang; Yu Zhang; Rui-Xue Tang; Dian-Zhong Luo; Gang Chen
Journal:  Oncotarget       Date:  2017-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.